Open Calculator 🌶️ Browse Protocols → Shop Compounds →
Peptide Protocol

Cagrilintide: long-acting amylin — appetite from a new angle.

Novel amylin receptor agonist with 7-day half-life. Combines powerfully with GLP-1 agonists (CagriSema) for superior weight loss.

Open Calculator 🌶️ All Protocols →
peppercalc.com · research use only
Home› Protocols› Cagrilintide
Amylin Analog Research Use Only

Cagrilintide
Dosage Protocol

Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. Unlike GLP-1 agonists, it acts on amylin receptors in the brain to reduce appetite and slow gastric emptying through a distinct mechanism. When combined with semaglutide (the CagriSema combination), it has demonstrated superior weight loss outcomes compared to either compound alone in Phase 3 trials.

0.3–2.4 mg
Weekly Dose
16–32 weeks
Cycle
SubQ
Route
Once weekly
Frequency
Overview

What is Cagrilintide?

Cagrilintide is a synthetic analog of human amylin — a peptide hormone co-secreted with insulin from pancreatic beta cells. It acts on amylin receptors (AMY1, AMY2, AMY3) in the area postrema, hypothalamus, and brainstem to signal satiety, reduce food intake, and slow gastric emptying. The acylation modification provides a ~7-day half-life enabling once-weekly dosing.

Phase 3 REDEFINE trials of cagrilintide 2.4 mg + semaglutide 2.4 mg (CagriSema) showed approximately 22% body weight reduction at 68 weeks, outperforming semaglutide alone. As a standalone agent, cagrilintide demonstrates meaningful weight reduction with a complementary mechanism to GLP-1 agonists, making it particularly valuable in combination protocols.

🧠
Amylin Receptor Agonism
Activates AMY1/2/3 receptors in the area postrema and hypothalamus, producing central satiety signaling and appetite suppression distinct from GLP-1 pathways.
🐌
Gastric Emptying Delay
Slows gastric emptying independently of GLP-1, prolonging post-meal satiety and reducing caloric intake through complementary peripheral mechanisms.
🔗
GLP-1 Synergy
Amylin and GLP-1 pathways converge on overlapping hypothalamic satiety circuits, producing additive or synergistic appetite suppression when combined.
⚖️
Body Weight Reduction
Phase 3 data show ~22% weight loss with CagriSema vs ~15% with semaglutide alone — demonstrating clinically meaningful additive benefit.
Dosing Protocol

Dosing Schedule

Parameters documented in published preclinical and clinical research.

⚠️ Research use only. The following documents parameters from published preclinical and clinical research. Not medical advice. Not for human consumption. Consult a licensed healthcare professional before any use.
PhaseDoseFrequencyDurationNotes
Start0.3 mgOnce weeklyWeeks 1–4SubQ. Slow titration to minimize GI side effects.
Titration0.6 → 1.2 → 1.8 mgOnce weeklyWeeks 5–16Increase every 4 weeks per tolerance.
Maintenance2.4 mgOnce weeklyWeeks 16+Target maintenance dose from Phase 3 trials.
Combination2.4 mg + sema 2.4 mgOnce weeklyPer protocolCagriSema combination for superior weight loss outcomes.
Safety Profile

Safety & Side Effects

✓ Generally Well Tolerated
Complementary mechanism to GLP-1 — different side effect profile
Phase 3 RCT data for CagriSema combination
Once-weekly dosing for convenience
No significant hypoglycemia risk as monotherapy
⚠ Potential Concerns
GI side effects: nausea, vomiting, constipation (less than GLP-1 alone)
Not yet FDA-approved as standalone therapy
Injection site reactions possible
Long-term cardiovascular data still accumulating
⚠️
Research use onlyThis page is an educational reference. None of this constitutes medical advice. Consult a qualified professional before any use. All compounds are for research purposes only.
Evidence Base

Academic References

  1. [1]
    Enebo LB, et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management. Lancet. 397(10286):1736–48. PubMed ↗
  2. [2]
    Frias JP, et al. (2023). Cagrilintide plus semaglutide 2.4 mg vs semaglutide 2.4 mg in T2D and obesity. N Engl J Med. 389:1969–80. PubMed ↗
  3. [3]
    Lau DCW, et al. (2021). Efficacy and safety of cagrilintide over 26 weeks in a randomized phase 2 trial. Lancet. 398(10315):1961–72. PubMed ↗
  4. [4]
    Rowlands J, et al. (2023). Amylin and its analogues: a friend or foe for treatment of type-2 diabetes. Diab Obes Metab. 25(11):3184–96. PubMed ↗
Recommended Source
Source your compounds at White Market Peptides
Use code PEPPERCALC10 for 10% off + free 2-day shipping over $200
Shop Now →